Thermal fixing device
    81.
    发明授权
    Thermal fixing device 失效
    热固定装置

    公开(公告)号:US5386281A

    公开(公告)日:1995-01-31

    申请号:US64805

    申请日:1993-05-21

    IPC分类号: G03G15/20 G03G21/00

    CPC分类号: G03G15/2064

    摘要: A thermal fixing device including a pair of rotating rollers which are press-contacted to each other, a heating section associated with at least one of the rollers and an image supporter having an unfixed toner image which is passed through a gap between the rollers so that the unfixed toner image is thermally (melt) fixed, the heating section having an integral structure type heating and cooling device which includes a cooler and a heater acting as a support, and wherein the fixing device further includes a thin endless metal belt which rotates while contacting the integral structure type device and which has a non-adhesive film on the outer surface of the belt, and a drive roller which drives the endless metal belt for rotation while applying tension to the endless metal belt. The surface temperature at a portion where the endless metal belt is in pressure-contact with the image supporter is first increased to a temperature (Tm) near the melting point of the toner and then cooled so that the image supporter can be stripped prior to the endless metal belt, and so that the temperature is higher than the glass transition point of the toner and lower than the softening point of the toner.

    摘要翻译: 一种热定影装置,包括彼此压接的一对旋转辊,与至少一个辊相关联的加热部分和具有通过辊之间的间隙的未定影调色剂图像的图像载体,使得 未定影的调色剂图像被热(熔融)固定,加热部分具有包括冷却器和作为支撑件的加热器的整体结构型加热和冷却装置,并且其中定影装置还包括薄的环形金属带,其旋转同时 接触一体结构型装置,并且在带的外表面上具有非粘性膜;以及驱动辊,其驱动环形金属带旋转同时向环形金属带施加张力。 首先将环形金属带与图像载体压力接触的部分的表面温度升高到接近调色剂熔点的温度(Tm),然后冷却,使图像支持体在 并且使得温度高于调色剂的玻璃化转变点并低于调色剂的软化点。

    Process for preparing cordierite
    83.
    发明授权
    Process for preparing cordierite 失效
    堇青石制备工艺

    公开(公告)号:US5089456A

    公开(公告)日:1992-02-18

    申请号:US606281

    申请日:1990-10-31

    摘要: A process for preparing a cordierite, which includes dissolving a silicon compound, an aluminum compound and a magnesium compound in a molar ratio of 1:0.7 to 1:0.3 to 0.5 in a complexing agent represented by the formula R(OCH.sub.2 CH.sub.2).sub.n OH, wherein R is an alkyl group and n is an integer of 1 to 4; heating the resulting solution to bring about a ligand exchange reaction of the silicon compound, aluminum compound and magnesium compound with the complexing agent; conducting hydrolysis to form a gel; drying the gel and sintering the dried gel at 800.degree. to 1450.degree. C.

    摘要翻译: 一种制备堇青石的方法,其包括在由式R(OCH 2 CH 2)nOH表示的络合剂中将摩尔比为1:0.7至1:0.3至0.5的硅化合物,铝化合物和镁化合物溶解,其中 R为烷基,n为1〜4的整数。 加热所得溶液以引起硅化合物,铝化合物和镁化合物与络合剂的配体交换反应; 进行水解以形成凝胶; 干燥凝胶并将干燥的凝胶烧结在800°至1450℃。

    Coin receiving apparatus for a vending machine
    84.
    发明授权
    Coin receiving apparatus for a vending machine 失效
    用于自动售货机的硬币接收装置

    公开(公告)号:US5050719A

    公开(公告)日:1991-09-24

    申请号:US450750

    申请日:1989-12-14

    申请人: Kazuo Shimizu

    发明人: Kazuo Shimizu

    CPC分类号: G07D5/02 G07D3/00 G07D5/08

    摘要: A coin receiving apparatus for a vending machine is disclosed which has a coin detector for producing an output corresponding to the diameter of a deposited coin. One or more additional coin detectors of a differential transformer type are sequentially arranged adjacent to the coin diameter detector in the coin detection path for producing an output corresponding to coin characteristics other than the coin diameter. A coin determination circuit judges whether the deposited coin is true or false in response to the detected outputs from the respective coin detectors. A coin receipt control circuit responsive to the true or false judgement output from the coin determination circuit controls the receipt or return of the deposited coin. The deposited coin is received in the receiving apparatus if the detected outputs from all of the coin detectors indicate that the deposited coin is true. A successive deposit determination circuit judges whether the last deposited coin passes through an initial coin detector on the coin detection path before the preceding deposited coin passes through a final coin detector. A timer starts to operate when the deposited coin passes through the final coin detector and responsive to an output of the successive deposit determination circuit. A determination output control circuit applies the true judgement output from the coin determination circuit to the coin receipt control circuit only when the timer does not operate after the deposited coin passes through the final coin detector. The coin receiving apparatus having such a successive deposit determination circuit, timer and determination output control circuit reduces the coin return ratio.

    Mechanical pencil
    86.
    发明授权
    Mechanical pencil 失效
    自动铅笔

    公开(公告)号:US4382706A

    公开(公告)日:1983-05-10

    申请号:US260486

    申请日:1981-05-04

    摘要: A mechanical pencil including a main body divided into first and second members which are rotatable relative to one another. An inner mechanism is provided, primarily in the first member of the body, including a chuck for gripping leads, a chuck tightening member for tightening the chuck disposed around the chuck, a chuck tightening member receiver, and a lead case coupled at a front end portion to the chuck. In a preferred embodiment, a push member is coupled at a front end to the lead case while a spring biases the inner mechanism rearwardly. A mechanism is provided for converting the relative rotation of the first and second members to axial movement of the inner mechanism between retracted and writing positions.

    摘要翻译: 一种自动铅笔,包括分为第一和第二构件的主体,所述第一和第二构件可相对于彼此旋转。 提供了主要在主体的第一构件中的内部机构,包括用于夹紧引线的卡盘,用于紧固设置在卡盘周围的卡盘的卡盘紧固构件,卡盘紧固构件接收器和联接在前端的引导壳体 部分到卡盘。 在优选实施例中,推动构件在前端联接到引导壳体,同时弹簧将内部机构向后偏置。 提供了一种机构,用于将第一和第二构件的相对旋转转换成缩回位置和书写位置之间的内部机构的轴向运动。

    Fused heterocyclic derivative and pharmaceutical use thereof
    88.
    发明授权
    Fused heterocyclic derivative and pharmaceutical use thereof 有权
    熔融杂环衍生物及其药物用途

    公开(公告)号:US09115144B2

    公开(公告)日:2015-08-25

    申请号:US14240157

    申请日:2012-08-23

    摘要: Compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level and the like. Fused heterocyclic derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, or prodrugs thereof, or pharmaceutically acceptable salts thereof. In the formula (I), ring U represents C6-10 aryl or the like; R1 independently represents a hydrogen atom, a hydroxy group, C1-6 alkyl or the like; m represents an integral number from 1 to 2; ring Q represents 5-membered heteroaryl; n represents an integral number from 1 to 3; R2 independently represents a hydrogen atom, a halogen atom, C1-6 alkyl or the like.

    摘要翻译: 可用作预防或治疗与血清尿酸水平异常等有关的疾病的药剂的化合物。 具有黄嘌呤氧化酶抑制活性的由下式(I)表示的稠合杂环衍生物,可用作预防或治疗与血清尿酸水平异常有关的疾病或其前药或其药学上可接受的盐。 在式(I)中,环U表示C6-10芳基等; R1独立地表示氢原子,羟基,C1-6烷基等; m表示从1到2的整数; 环Q表示5元杂芳基; n表示1〜3的整数; R2独立地表示氢原子,卤素原子,C1-6烷基等。

    Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
    89.
    发明授权
    Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof 有权
    吡唑衍生物,含有该吡唑衍生物的药物组合物,其医药用途及其生产用中间体

    公开(公告)号:US08324176B2

    公开(公告)日:2012-12-04

    申请号:US12421236

    申请日:2009-04-09

    IPC分类号: A61K31/7028 C07H17/02

    摘要: The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents —RB, —CORC etc. in which RB represents an optionally substituted C1-6 alkyl group etc.; and RC represents an optionally substituted C1-6 alkyl group etc.; R4 represents H, an optionally substituted C1-6 alkyl group etc.; and R3, R5 and R6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

    摘要翻译: 本发明提供由以下通式表示的吡唑衍生物:其中R1表示H,任选取代的C 1-6烷基等; Q和T之一表示由通式表示的基团或由通式表示的基团:而另一个表示任选取代的C 1-6烷基等; R2表示H,卤素原子,OH,任意取代的C 1-6烷基等; X表示单键,O或S; Y表示任选取代的C 1-6亚烷基等; Z表示-RB,-CORC等,其中RB表示任选取代的C 1-6烷基等; 并且RC表示任选取代的C 1-6烷基等; R4代表H,任选取代的C 1-6烷基等; R3,R5和R6表示H,卤素原子等,其药学上可接受的盐或其前药,其在人SGLT1中表现出优异的抑制活性,并且可用作预防或治疗与高血糖相关的疾病的药剂,例如 糖尿病,葡萄糖耐量减低,空腹血糖受损,糖尿病并发症或肥胖症,以及与半乳糖水平升高相关的疾病,以及包含其的药物组合物,其制药用途及其生产用中间体。

    Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
    90.
    发明授权
    Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof 失效
    吡唑衍生物,含有该吡唑衍生物的药物组合物,其医药用途及其生产用中间体

    公开(公告)号:US07655632B2

    公开(公告)日:2010-02-02

    申请号:US12104890

    申请日:2008-04-17

    IPC分类号: A01N43/04 A61K31/70

    CPC分类号: C07H17/02

    摘要: The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents a single bond, a C1-6 alkylene group etc.; Z represents CO or SO2; R4 and R5 represent H, an optionally substituted C1-6 alkyl group etc.; and R3, R6 and R7 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

    摘要翻译: 本发明提供由以下通式表示的吡唑衍生物:其中R1表示H,任选取代的C 1-6烷基等; Q和T之一表示由通式表示的基团或由通式表示的基团:而另一个表示任选取代的C 1-6烷基等; R2表示H,卤素原子,OH,任意取代的C 1-6烷基等; X表示单键,O或S; Y表示单键,C1-6亚烷基等; Z表示CO或SO2; R4和R5代表H,任选取代的C 1-6烷基等; R 3,R 6和R 7表示H,卤素原子等,其药学上可接受的盐或其前药,其在人SGLT1中表现出优异的抑制活性,并且可用作预防或治疗与高血糖相关的疾病 糖尿病,糖尿病并发症或肥胖症,以及包含该药物组合物的药物组合物,其药学用途及其生产用中间体。